Developing and commercializing drugs for the treatment of ocular diseases.
Developing and commercializing drugs for the treatment of ocular diseases, with a special focus on retinal pathologies. Fovea has multiple clinical programs ongoing in retinal degeneration, macular edema, glaucoma, and inflammation.
Fovea was acquired by Sanofi-aventis in 2009 for up to EUR 390 million.
Human Health
Industry
Biotech
Status
Realised
Location
France